Opioid Addiction Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Reasons to buy the ‘Opioid Addiction Market’ opportunity assessment report:

The report offers:

  • A detailed overview of opioid addiction, inclusive opioid use disorder (OUD), and opioid withdrawal syndrome (OWS), including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized opioid addiction therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for opioid addiction. The most promising candidates in late-stage development are profiled.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the opioid addiction market.
  • Analysis of the current and future market competition in the 8MM opioid addiction therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

How is our ‘Opioid Addiction Market’ report unique from other reports in the market?

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 8MM opioid addiction therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the opioid addiction therapeutics market in the future.

We recommend this valuable source of information to anyone involved in:

  • Pharma and Biotech Companies – CNS Drug Manufacturers and Suppliers
  • Consulting and Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
  • Pharmaceutical Industry Suppliers/Pharma Manufacturers (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease)/Distributors
  • Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)/Parallel Trade Organisations
  • Healthcare Organisations/Healthcare Technology Leaders and Start-ups

To Get a Snapshot of the Opioid Addiction Market Report

Download a Free Sample Report

Opioid Addiction Market Report Overview

The opioid addiction market across the 8MM (the US, Canada, France, Germany, Italy, Spain, the UK, and Australia) was valued at $2 billion in 2023 and the market will grow at a CAGR of more than 1% from 2023 to 2033. The launch of four novel pipeline agents including Cannabidiol, Mazindol CR, Probenecid, and TRV‐734 will drive market growth over the forecast period.

Opioid Addiction Market Outlook 2023-2033 ($ Billion)
Opioid Addiction Market Outlook 2023-2033 ($ Billion)Buy the Full Report to Know More About the Opioid Addiction Market Forecast
Download a Free Sample Report

The opioid addiction market research report offers an overview of epidemiology, symptoms, diagnosis, and disease management. The report covers key topics, including strategic competitor assessment and market characterization that will help in identifying opioid addiction business strategies for opioid addiction market participants. In addition, the report’s data on unmet needs and clinical trial mapping will assist in understanding market gaps and making actionable predictions.

Market Size (2023) $2 billion
CAGR (2023-2033) >1%
Key Countries (8MM) ·       United States

·       Canada

·       France

·       Germany

·       Italy

Key Drug Classes ·       Synthetic Opioid Analgesics

·       Opioid Receptor Antagonist

·       Dual Synthetic Opioid Analgesic

·       Alpha 2A Adrenergic Receptor Agonist (ADRA2A)

·       Pipeline

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Opioid Addiction Market Dynamics

The opioid addiction market is dominated by two main opioid agonist therapies including methadone and buprenorphine. These are widely available in cheap generic forms, which will continue to dominate the market throughout the forecast period, limiting the uptake of more expensive branded products. However, Cannabidiol, Mazindol CR, Probenecid, and TRV‐734 are anticipated to launch across all the 8MM during the forecast period. Cannabidiol and Mazindol CR are expected to be used as potential adjunctive treatments and the standard of care thereby driving an increase in the OUD market.

Buy the Full Report for Additional Insights on the Key Opioid Addiction Market Dynamics
Download a Free Sample Report

Opioid Addiction Market Segmentation by Country

The key countries in the opioid addiction market are the US, Canada, France, Germany, Italy, Spain, the UK, and Australia. In 2023, the United States accounted for the highest share of the total opioid addiction market. The country’s growth is attributed to the larger OUD population, higher drug prices, and wider, and availability of opioid therapies.

Opioid Addiction Market Analysis by Country, 2023 (%)
Opioid Addiction Market Analysis by Country, 2023 (%)Buy the Full Report for Country-Wise Insights on the Opioid Addiction Market
Download a Free Sample Report

Opioid Addiction Market Segmentation by Drug Classes

The key drug classes in the opioid addiction market are synthetic opioid analgesics, opioid receptor antagonist, dual synthetic opioid analgesicalpha 2a adrenergic receptor agonist (adra2a), and pipeline. In 2023, the synthetic opioid analgesics drug class sales were the highest in the opioid addiction market.

Opioid Addiction Market Analysis by Drug Classes, 2023 (%)
Opioid Addiction Market Analysis by Drug Classes, 2023 (%)Buy the Full Report for Drug-Class Insights on the Opioid Addiction Market

Download a Free Sample Report

Segments Covered in this Report

Opioid Addiction Market Country Outlook ($ Billion, 2023-2033)

  • The United States
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • The United Kingdom
  • Australia

Opioid Addiction Market Drug Classes Outlook (%, 2023-2033)

  • Synthetic Opioid Analgesics
  • Opioid Receptor Antagonist
  • Dual Synthetic Opioid Analgesic
  • Alpha 2A Adrenergic Receptor Agonist (ADRA2A)
  • Pipeline
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Co
Novartis AG
Indivior Plc
Camurus AB
US WorldMeds LLC
Rosemont Pharmaceuticals Ltd
Molteni Farmaceutici
Hexal AG
Trevena Inc
Mallinckrodt LLC
Omeros Corp
Jazz Pharmaceuticals Inc
Braeburn Inc
Mundipharma Pty Ltd
Orexo US Inc
Alkermes Inc
Ananda Scientific Inc
RB Pharmaceuticals Ltd
NLS Pharmaceutics AG
Accord Healthcare (Pty) Ltd
Palisades Therapeutics
AphioTx Inc

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of Opioid Addiction: Opioid Use Disorder

3.2. Classification of Opioid Use Disorder

3.3. Overview of Opioid Withdrawal Syndrome

3.4. Pathophysiology of Opioid Addiction

3.5. Opioid Addiction SWOT Analysis

4. Epidemiology

4.1. 12-Month Total Prevalent Cases of OUD, Men and Women, Ages ≥18 Years, 2023–33

4.2. Age-Specific Trends in 12-Month Total Prevalent Cases of OUD, Both Sexes, 2023

4.3. Sex-Specific 12-Month Total Prevalent Cases of OUD, Ages ≥18 Years, 2023

4.4. 12-Month Total Prevalent Cases of OUD by Severity, Both Sexes, Ages ≥18 Years, 2023

4.5. 12-Month Diagnosed Prevalent Cases of OUD, Men and Women, Ages ≥18 Years, 2023–33

4.6. Age-Specific Trends in 12-Month Diagnosed Prevalent Cases of OUD, Both Sexes, 2023

4.7. Sex-Specific 12-Month Diagnosed Prevalent Cases of OUD, Ages ≥18 Years, 2023

4.8. 12-Month Diagnosed Prevalent Cases of OUD by Severity, Both Sexes, Ages ≥18 Years, 2023

4.9. 12-Month Total Prevalent Cases of OWS, Men and Women, Ages ≥18 Years, 2023–33

4.10. 12-Month Diagnosed Prevalent Cases of OWS, Men and Women, Ages ≥18 Years, 2023–33

4.11. Sources Used to Forecast 12-Month Total Prevalent Cases of OUD

4.12. Sources Used to Forecast 12-Month Total Prevalent Cases and 12-Month Diagnosed Prevalent Cases of OUD by Severity

4.13. Sources Used to Forecast 12-Month Total Prevalent Cases and 12-Month Diagnosed Prevalent Cases of OWS

4.14. Sources and Methodology

5. Current Treatment Options

5.1. Treatment Paradigm for Opioid Addiction

5.2. Treatment Paradigm

5.3. Timeline of Opioid Addiction Treatment by Strategy

5.4. Current Treatment Options

5.5. Product Profile: Oral Methadone Hydrochloride (Methadose, Methaddict)

5.6. Product Profile: Morphine Sulfate ER (Substitol)

5.7. Product Profile: Naltrexone ER (Vivitrol)

5.8. Product Profile: Oral Naltrexone (Revia)

5.9. Product Profile: Oral Buprenorphine (Subutex)

5.10. Product Profile: Buprenorphine + Naloxone ODT (Zubsolv)

5.11. Product Profile: Oral Buprenorphine + Naloxone (Suboxone)

5.12. Product Profile: Buprenorphine LA (Sublocade)

5.13. Product Profile: Buprenorphine Implant (Probuphine, Sixmo)

5.14. Product Profile: Buprenorphine PR (Buvidal, Brixadi)

5.15. Product Profile: Lucemyra (lofexidine)

5.16. Patient Flow: Opioid Addiction in 2023 Across the 8MM

6. Unmet Needs and Opportunities

6.1. Unmet Needs in Opioid Addiction

6.2. Non-Opioid with an Opioid-Comparable Efficacy Profile

6.3. Designing Clinical Trials Reflective of Real-World Scenarios

6.4. Greater Awareness and Education of Prescribers

6.5. Improving Compliance Rates Through the Offer of Digital Therapeutics and Additional Behavioral Interventions

7. R&D Strategies

7.1. Trends in Clinical Trial Design in Opioid Addiction

7.2. Trends in Deal-Making in Opioid Addiction

8. Pipeline Assessment

8.1. Opioid Addiction Pipeline Overview

8.2. Late-Stage Pipeline Agents for Opioid Addiction

8.3. Product Profile: Ananda Scientific’s Cannabidiol

8.4. Product Profile: NLS Pharmaceutical’s Mazindol CR

8.5. Product Profile: AphioTx Inc.’s Probenecid

8.6. Product Profile: Trevena Inc.’s TRV-734

8.7. Opioid Addiction: Clinical Trials (Phase II/III) Overview

9. Market Outlook

9.1. Opioid Addiction Market Forecast

9.2. Market Drivers and Barriers

10. Appendix

10.1. Primary Research: KOL Information

10.2. Bibliography

10.3. About the Authors

11. Contact Us

Frequently asked questions

Opioid Addiction Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Opioid Addiction Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Opioid Addiction Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 in real time.

  • Access a live Opioid Addiction Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.